QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 4.11    
    


        "CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN OMITTED AND HAVE BEEN SEPARATELY FILED WITH THE COMMISSION. CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS, WHICH ARE IDENTIFIED BY ***."


 
 

LICENSE AGREEMENT  
    


        Effective as of February 5, 2004 ("EFFECTIVE DATE"), GENETIC TECHNOLOGIES LIMITED, having an office at 60
Hanover Street, Fitzroy, Victoria 3065, Australia ("GTG") and LABORATORY CORPORATION OF AMERICA HOLDINGS, a Delaware corporation having an office at 430
South Spring Street, Burlington, NC 27215, USA ("LICENSEE"), agree as follows: 


ARTICLE I  


 BACKGROUND  


	1.1
	As
a result of privately funded research over the course of many years, GTG now holds certain intellectual property rights in a variety of countries throughout the world relating to
methods and processes used to extract gene discovery and diagnostic utility from the non-coding region of genomes.



	1.2
	LICENSEE
wishes to acquire licenses under and to obtain access to GTG's non-coding patents to the extent that they are required in accordance with applicable law in order
to: 1) provide clinical laboratory diagnostic testing services and other testing services offered by LICENSEE and/or SUBSIDIARIES of LICENSEE on humans in the United States, it territories, and
Canada ("DIAGNOSTIC TESTING PURPOSE"); and 2) provide and conduct contract clinical trials and research protocols and services in the United States, its territories, and Europe solely for
(i) assisting third parties, including, but not limited to pharmaceutical companies; and (ii) internal purposes of LICENSEE and/or SUBSIDIARIES of LICENSEE in connection with regulatory
compliance ("CLINICAL TRIALS PURPOSE").



	1.3
	GTG
is prepared to grant a non-exclusive license to LICENSEE under its non-coding patents, subject to the terms and conditions of this AGREEMENT. 


ARTICLE II  


 GENERAL DEFINITIONS AND RELATIONSHIPS AMONG DEFINITIONS  


	2.1
	"AGREEMENT"
means this document, its attachments, all addenda, schedules, exhibits, appendices, and any amendments to the foregoing.



	2.2
	"CLINICAL
TRIALS LICENSED SERVICES" means research services and clinical trials performed by LICENSEE or a SUBSIDIARY of LICENSEE and that but for the license granted herein would
infringe or contribute to the infringement of one or more claims of a LICENSED PATENT.



	2.3
	"CONFIDENTIAL
INFORMATION" means any and all information which is disclosed by either party to the other verbally, electronically, visually, or in a written or other tangible form
which is either identified at the time of disclosure as confidential or should be reasonably understood to be confidential or proprietary. CONFIDENTIAL INFORMATION includes, but is not limited to, the
specific terms and/or conditions of this AGREEMENT, trade secrets, ideas, processes, formulas, programs, software, source of supply, technology, discoveries, developments, inventions, techniques,
marketing plans, strategies, forecasts, unpublished financial statements, prices, costs, and customer lists.



	2.4
	"DIAGNOSTIC
TESTING LICENSED SERVICES" means diagnostic service testing, or other testing service offered by LICENSEE and/or SUBSIDIARIES of LICENSEE (i) performed by 







 

LICENSEE
or a SUBSIDIARY of LICENSEE; and (ii) that but for the license granted herein would infringe or contribute to the infringement of one or more claims of a LICENSED PATENT. 



	2.5
	"EXCLUDED
FIELD" means ***



	2.6
	"EXCLUSION
TIME PERIOD" means the period from the EFFECTIVE DATE until August 31, 2006.



	2.7
	"FIELD
OF USE" means, during the EXCLUSION TIME PERIOD, diagnostic service testing and other testing services offered by LICENSEE and/or SUBSIDIARIES of LICENSEE for humans and
clinical trials and research, other than the EXCLUDED FIELD, and upon expiration of the EXCLUSION TIME PERIOD means diagnostic service testing and other testing services offered by LICENSEE and/or
SUBSIDIARIES of LICENSEE for humans and clinical trials and research without limitation.



	2.8
	GTG
and LICENSEE may be commonly referred to as "parties" (in singular and plural usage, as required by the context).



	2.9
	"LICENSED
PATENT(S)" means individually or collectively (i) the United States patents of GTG listed in the attached Exhibit A; (ii) all reissues, reexaminations,
divisionals, continuations, continuations-in-part, substitutions, or other applications claiming priority from such patents and any patents which may issue on such other
applications, or extensions of such patents; and (iii) foreign counterparts of any of the foregoing.



	2.10
	"LICENSED
SERVICES" means CLINICAL TRIALS LICENSED SERVICES and DIAGNOSTIC TESTING LICENSED SERVICES.



	2.11
	***



	2.12
	"SUBSIDIARY"
means any corporation, company or other legal entity, in which more than fifty percent (50%) of the shares entitled to vote for the election of directors or persons
performing similar functions are, now or hereafter, owned or controlled, directly or indirectly by a party hereto, or jointly by the parties hereto; provided, however, that any corporation, company or
other legal entity shall be a SUBSIDIARY only for as long as such ownership or control exists.



	2.13
	"TERRITORY"
means Canada and the United States of America (including its territories).



	2.14
	"TERM"
means from the EFFECTIVE DATE until there is no longer a VALID PATENT CLAIM (due to expiration or otherwise), except as otherwise provided in Article VII.



	2.15
	"VALID
PATENT CLAIM" shall mean any claim in a filed and unabandoned patent application or unexpired patent with the LICENSED PATENTS, which claim has not been held unpatentable,
unenforceable, or invalid by a decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, and which has not been finally
abandoned or admitted to be invalid or unenforceable through reissue, disclaimer or otherwise. 


ARTICLE III  


 RELEASE  


	3.1
	Upon
execution of this AGREEMENT by both parties and payment in full by LICENSEE of the *** to GTG, GTG, and any person or entity claiming through GTG (including without limitation
any affiliates, predecessors, successors or assigns of GTG), hereby waive, release and forever discharge LICENSEE, all SUBSIDIARIES of LICENSEE,  and their
respective successors, assigns, directors, officers, employees and agents, both current and former (collectively, the "RELEASED PARTIES") from
any and all claims, suits, demands, actions, losses, costs, damages, expenses, liabilities and obligations whatsoever, whether known or unknown, arising from or relating to 


2







 

(a) any
acts or omissions of the RELEASED PARTIES on or before the *** or ***, whichever is later (the "RELEASE DATE"), (b) any events, occurrences, conditions or circumstances occurring
on or before the RELEASE DATE, or (c) any transactions, relationships, arrangements or other matters of any kind or nature existing at any time on or before the RELEASE DATE (collectively, the
"RELEASED MATTERS"). This waiver and release includes, but is not limited to, any claims arising from or related to the infringement or misappropriation, or alleged infringement or misappropriation,
of any intellectual property or other proprietary rights of GTG (including without limitation the LICENSED PATENTS) by the RELEASED PARTIES. 



	3.2
	GTG
further agrees that it will not institute or participate in any legal action or administrative complaint against the RELEASED PARTIES arising out of or related to the RELEASED
MATTERS. In the event of a breach of this Article 3 of this AGREEMENT, the RELEASED PARTIES shall be entitled to recover from GTG attorneys' fees and expenses incurred by the RELEASED PARTIES
defending such lawsuit filed by, on behalf of or otherwise involving GTG. 


ARTICLE IV  


 GRANT TO LICENSEE  


	4.1
	Subject
to the terms and conditions of this AGREEMENT, GTG hereby grants to LICENSEE, during the TERM of this AGREEMENT:



	(i)
	A
non-exclusive, non-assignable, annual fee-bearing license under the LICENSED PATENTS (without the right to sublicense except to
LICENSEE's SUBSIDIARIES) to perform, use, sell, and offer to sell DIAGNOSTIC TESTING LICENSED SERVICES in the FIELD OF USE solely within the TERRITORY for the DIAGNOSTIC TESTING PURPOSE; and



	(ii)
	A
non-exclusive, non-assignable, annual fee-bearing license under the LICENSED PATENTS (without right to sublicense except to
LICENSEE's SUBSIDIARIES) to perform, use, sell, and offer to sell CLINICAL TRIALS LICENSED SERVICES in the FIELD OF USE in the United States, its territories, and Europe (regardless of where the
samples originate or where the sponsor may be located) for the CLINICAL TRIALS PURPOSE.






	4.2
	All
rights not explicitly granted to LICENSEE are reserved by GTG. Not limiting the foregoing, LICENSEE acknowledges that it is not granted any rights to any other patents or other
intellectual property rights of GTG or any third party.



	4.3
	The
rights and licenses granted by GTG in this AGREEMENT are personal to LICENSEE. Except as set forth in Section 4.4 and Section 11.6, LICENSEE shall not assign or
otherwise transfer (by operation of law or otherwise) any license or right granted hereunder or any interest therein, without the prior written consent of GTG (which may be withheld in GTG's sole and
absolute discretion). Any attempted assignment or transfer without such prior written consent shall be void and shall upon written notice by GTG terminate all rights of LICENSEE under this AGREEMENT.



	4.4
	LICENSEE
may extend the license granted under this AGREEMENT to SUBSIDIARIES of LICENSEE provided that LICENSEE ensures that such SUBSIDIARIES are bound to the same terms and
conditions of this AGREEMENT as is LICENSEE (except that such SUBSIDIARIES shall not be obligated ***, it being understood that payments by LICENSEE of the amounts under *** constitutes *** for
LICENSEE and all SUBSIDIARIES of LICENSEE).



	4.5
	***


3







 
ARTICLE V  


 CONSIDERATION  


	5.1
	Subject
to Section 5.2, LICENSEE agrees to pay to GTG the QUARTERLY LICENSE ANNUITY commencing on *** (such first payment constituting payment for the period from *** until
***. Such QUARTERLY LICENSE ANNUNITY payments are due and payable to GTG on January 1, April 1, July 1, and October 1 of each year of the TERM.



	5.2
	LICENSEE
agrees to pay GTG *** upon execution of this AGREEMENT (the "PREPAYMENT"). The PREPAYMENT shall constitute a non-refundable credit against QUARTERLY LICENSE
ANNUITY payments required under this AGREEMENT. ***



	5.3
	All
payments required under this AGREEMENT shall be sent by electronic wire transfer to: 




Key
Bank

#307070267

1130 Haxton Drive

Fort Collins, Colorado 80525

Account: Genetic Technologies Limited

Account Number: 76009 000 2576 




	5.4
	LICENSEE
agrees to pay interest of *** per year or the maximum rate allowed by law, whichever is less, on fees payable but not paid to GTG when due.



	5.5
	MATERIAL
BREACH: A breach of any provision of this Article V or part thereof by LICENSEE shall be deemed a material breach. 




ARTICLE VI  


 WAIVER  


        No waiver by either party, express or implied, of any breach of any term, condition, or obligation of this AGREEMENT by the other party shall be construed as a
waiver of any subsequent breach of that term, condition, or obligation, or of any other term, condition, or obligation of this AGREEMENT of the same or different nature. 


ARTICLE VII  


 TERM AND TERMINATION OF AGREEMENT  


	7.1
	This
AGREEMENT shall be in effect for the TERM, unless terminated earlier as provided herein.



	7.2
	Either
party shall have the right to terminate this AGREEMENT upon any material breach of any term or condition of this AGREEMENT by the other party, which has not been corrected
within thirty (30) days after receipt of a notice in writing with reference to this Section 7.2 and such termination shall be without prejudice to any other rights or claims the
aggrieved party may have against the other party. GTG shall have the right to terminate this AGREEMENT upon written notice in the event that LICENSEE shall become involved in insolvency, dissolution,
bankruptcy, or receivership proceedings affecting the operation of LICENSEE's business, or in the event that LICENSEE discontinues business for any reason.



	7.3
	LICENSEE
shall have the right to terminate this AGREEMENT at any time by providing GTG with thirty (30) days written notice of such termination.



	7.4
	Termination
or expiration of this AGREEMENT shall not affect any obligation owed by LICENSEE to GTG prior to the termination or expiration. Upon termination or expiration of this
AGREEMENT:



	7.4.1
	all
licenses granted hereunder shall immediately cease. 





4







 



	7.4.2
	the
parties shall promptly return all CONFIDENTIAL INFORMATION and copies thereof of the other party to the other party or certify in writing that they have destroyed
all CONFIDENTIAL INFORMATION and copies thereof.



	7.4.3
	LICENSEE
shall pay GTG the pro-rated amount of the quarterly payment set forth in Section 5.1 that had accumulated as of the date of termination or
expiration for that year of the AGREEMENT.






	7.5
	SURVIVAL:
Articles II, III, VIII and X shall survive the termination or expiration of this AGREEMENT. 


ARTICLE VIII  


 CONFIDENTIALITY, PUBLICITY, PRESS RELEASES AND MARKING  


	8.1
	LIMITATIONS
ON USE AND DISCLOSURE: The parties agree that the terms and conditions set forth in this AGREEMENT are CONFIDENTIAL INFORMATION. The CONFIDENTIAL INFORMATION disclosed by
either party ("DISCLOSING PARTY") to the other party ("RECEIVING PARTY") constitutes the confidential and proprietary information of the DISCLOSING PARTY and the RECEIVING PARTY agrees to treat all
CONFIDENTIAL INFORMATION of the other in the same manner as it treats its own similar proprietary information, but in no case will the degree of care be less than reasonable care. The RECEIVING PARTY
shall use CONFIDENTIAL INFORMATION of the DISCLOSING PARTY only in performing under this AGREEMENT and shall retain the CONFIDENTIAL INFORMATION in confidence and not disclose to any third party
(except as authorized under this AGREEMENT) without the DISCLOSING PARTY's express written consent. The RECEIVING PARTY shall disclose the DISCLOSING PARTY's CONFIDENTIAL INFORMATION only to those
employees and contractors of the RECEIVING PARTY who have a need to know such information for the purposes of this AGREEMENT, and such employees and contractors must have entered into agreements with
the RECEIVING PARTY containing confidentiality provisions covering the CONFIDENTIAL INFORMATION, or similar confidential information, with terms and conditions at least as restrictive as those set
forth herein. Notwithstanding the foregoing, each party's confidentiality obligations hereunder shall not apply to information which as evidenced by written records:



	8.1.1
	is
already known to the RECEIVING PARTY, without an obligation of confidentiality, prior to disclosure by the DISCLOSING PARTY;



	8.1.2
	becomes
publicly available without fault of the RECEIVING PARTY;



	8.1.3
	is
rightfully obtained by the RECEIVING PARTY from a third party without restriction as to disclosure, or is approved for release by written authorization of the
DISCLOSING PARTY; or



	8.1.4
	is
developed independently by the RECEIVING PARTY without use of or access to the DISCLOSING PARTY's CONFIDENTIAL INFORMATION.






	8.2
	PERMITTED
USE AND DISCLOSURE: Each party hereto is permitted to disclose this AGREEMENT and use or disclose the CONFIDENTIAL INFORMATION disclosed to it by the other party:



	8.2.1
	To
the extent such use or disclosure is reasonably necessary in connection with complying with stock exchange rules; or



	8.2.2
	To
its legal and/or financial advisors, provided such advisors maintain the confidentiality of this AGREEMENT; or 





5







 



	8.2.3
	To
the extent such use or disclosure is reasonably necessary in prosecuting or defending litigation, complying with applicable law, governmental regulation or court
order, submitting information to tax or other governmental authorities, or otherwise exercising its rights hereunder; or



	8.2.4
	To
the extent necessary to enforce its rights under this AGREEMENT in connection with a legal proceeding or as required to be disclosed by law or governmental
regulation.



	8.2.5
	In
the instances set forth in this Sections 8.2.3 or 8.2.4, the RECEIVING PARTY shall provide reasonable advance written notice to DISCLOSING PARTY of such disclosure
and reasonably cooperate with the DISCLOSING PARTY in limiting such disclosure.






	8.3
	PUBLICITY
AND PRESS RELEASES: Neither party shall issue any press releases relating to this AGREEMENT without prior written approval of the other party; provided however, that:



	8.3.1
	Each
party shall be permitted to post a copy of or provide a link on its web site to any permitted disclosures made under this AGREEMENT;



	8.3.2
	Each
party may disclose the existence of the AGREEMENT only to the extent required to comply with any applicable law or regulation; and



	8.3.3
	LICENSEE
shall be able to disclose to SUBSIDIARIES of LICENSEE the existence of this AGREEMENT and the terms of this AGREEMENT, provided such SUBSIDIARIES maintain the
confidentiality of this AGREEMENT. 





ARTICLE IX  


 NOTICE  


	9.1
	Any
notice, request or statement hereunder shall be deemed to be sufficiently given or rendered when personally delivered, delivered by a major commercial rapid delivery courier
service or mailed by certified or registered mail, return receipt requested, and if given or rendered to LICENSEE, addressed to: 




Laboratory
Corporation of America Holdings

Attn: General Counsel

430 South Spring Street

Burlington, NC 27215

USA 




or,
if given or rendered to GTG, addressed to: 



Dr. Mervyn
Jacobson

Executive Chairman

Genetic Technologies Limited

60 Hanover Street

Fitzroy, Victoria 3065

Australia 




with
a copy to: 



Michael
A. DeSanctis, Esq.

Faegre & Benson LLP

3200 Wells Fargo Center

1700 Lincoln Street

Denver, CO 80203

USA 




6







 





or,
in any case, to such changed address or person as GTG or LICENSEE shall have specified to the other by written notice. 


ARTICLE X  


 REPRESENTATIONS AND WARRANTIES  


	10.1
	GTG
represents and warrants that it has the full right, power, and authority to enter into and perform its obligations under this AGREEMENT and grant to LICENSEE the license and
other rights as set forth herein, and there are no outstanding agreements, grants, licenses, encumbrances, liens, or agreements, either written or implied, inconsistent therewith or pursuant to which
this AGREEMENT or the parties' performance hereunder would violate, breach, or cause a default. GTG further represents and warrants that the LICENSED PATENTS are the only
patents owned or controlled by GTG that LICENSEE needs to practice the methods disclosed in the patents listed in Exhibit A.



	10.2
	The
execution, delivery, and performance of this AGREEMENT have been duly authorized by all necessary corporate actions on the part of GTG.



	10.3
	***



	10.4
	LICENSEE
represents and warrants that it has the full right, power, and authority to enter into and perform its obligations under this AGREEMENT, and there are no outstanding
agreements, grants, licenses, encumbrances, liens, or agreements, either written or implied, inconsistent therewith or pursuant to which this AGREEMENT or the parties' performance hereunder would
violate, breach, or cause a default.



	10.5
	LICENSEE
represents and warrants that the execution, delivery, and performance of this AGREEMENT have been duly authorized by all necessary corporate actions on the part of LICENSEE.



	10.6
	INDEMNIFICATION:



	10.6.1
	BY
LICENSEE: LICENSEE shall indemnify, hold harmless, and defend GTG, and GTG's SUBSIDIARIES, affiliates, officers, directors, representatives, employees, or agents
against any and all third party claims, causes of action, demands, judgments, settlements, expenses, or losses including, but not limited to, reasonable attorneys' fees and court costs arising out of
or in connection with: (i) any breach by LICENSEE of any representation, warranty, or covenant hereunder; (ii) the failure of LICENSEE to perform any covenants or obligations contained
in this AGREEMENT; or (iii) LICENSEE's negligent, reckless, or willful misconduct.



	10.6.2
	BY
GTG: GTG shall indemnify, hold harmless, and defend LICENSEE, and LICENSEE's SUBSIDIARIES, affiliates, officers, directors, representatives, employees, or agents
against any and all third party claims, causes of action, demands, judgments, settlements, expenses, or losses including, but not limited to, reasonable attorneys' fees and court costs arising out of
or in connection with: (i) any breach by GTG of any representation, warranty, or covenant hereunder; (ii) the failure of GTG to perform any covenants or obligations contained in this
AGREEMENT; or (iii) GTG's negligent, reckless, or willful misconduct.



	10.6.3
	The
indemnifying party's indemnification obligations under this Section 10.6 are conditioned upon the indemnified party (a) giving prompt notice of the
claim to the indemnifying party; (b) granting sole control of the defense or settlement of the claim or action to the indemnifying party; and (c) providing reasonable cooperation to the
indemnifying party and, at the indemnifying party's request and expense, assistance in the defense or settlement of the claim. 





7







 




	10.7
	DISCLAIMER
OF WARRANTIES: EXCEPT AS EXPRESSLY SET FORTH HEREIN, EACH PARTY EXPRESSLY DISCLAIMS, TO THE EXTENT ALLOWED BY APPLICABLE LAW, ANY AND ALL WARRANTIES OF ANY KIND, EXPRESS
OR IMPLIED, RELATING TO THE LICENSED PATENTS AND THE LICENSED SERVICES, INCLUDING WITHOUT LIMITATION THE WARRANTIES OF DESIGN, TITLE, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE (EVEN IF
INFORMED OF SUCH PURPOSE), NONINFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES, OR ARISING FROM A COURSE OF DEALING, USAGE OR TRADE PRACTICES, IN ALL CASES WITH RESPECT THERETO.



	10.8
	LIMITATION
OF LIABILITY: TO THE GREATEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, EXCEPT FOR A BREACH OF A PARTY'S OBLIGATIONS PURSUANT TO ARTICLE VIII, WITH RESPECT TO ANY CAUSE OF
ACTION RELATING TO OR ARISING FROM THIS AGREEMENT (WHETHER UNDER THIS ARTICLE X OR OTHERWISE): (I) NEITHER PARTY SHALL BE ENTITLED TO RECOVER FROM THE OTHER PARTY ANY SPECIAL, INCIDENTAL,
CONSEQUENTIAL OR PUNITIVE DAMAGES IN CONNECTION WITH THIS AGREEMENT OR ANY LICENSE GRANTED HEREUNDER, AND (II) NEITHER PARTY SHALL BE LIABLE FOR ANY AMOUNTS IN EXCESS OF THE TOTAL AMOUNTS PAID
TO GTG BY LICENSEE HEREUNDER DURING THE 12 MONTHS IMMEDIATELY PRECEDING THE EVENT GIVING RISE TO SUCH LIABILITY.



	10.9
	Nothing
contained in this AGREEMENT shall be construed as:



	10.9.1
	a
warranty or representation by GTG as to the validity or scope of any LICENSED PATENT except as provided expressly herein;



	10.9.2
	a
warranty or representation that any use or performance contemplated herein will be free from infringement of patents other than those LICENSED PATENTS under which
and to the extent to which licenses are in force hereunder;



	10.9.3
	an
agreement to bring or prosecute actions or suits against third parties for infringement or conferring any right to bring or prosecute actions or suits against
third parties for infringement;



	10.9.4
	conferring
any right to use by either party, in advertising, publicity, or otherwise, any trademark, trade name or name, or any contraction, abbreviation or
simulation thereof, of the other party;



	10.9.5
	conferring
by implication, estoppel or otherwise, upon LICENSEE, any license or other right under any intellectual property or patent, except that expressly granted
hereunder. 





ARTICLE XI  


 MISCELLANEOUS  


	11.1
	SERVICE
LITERATURE: To the extent practicable and consistent with LICENSEE's customary practices, LICENSEE will prominently display on any literature or other materials (in paper,
electronic or other format) distributed with or about any LICENSED SERVICES, as determined in LICENSEE's sole discretion, a notice indicating that any such LICENSED SERVICES are provided pursuant to a
license from GTG under the LICENSED PATENTS, which patents are owned by GTG.



	11.2
	CONSTRUCTION:
This AGREEMENT has been negotiated by the parties and their respective counsel. This AGREEMENT shall be interpreted fairly in accordance with its terms and without any
strict construction in favor of or against either party. This AGREEMENT shall not be 


8







 

construed
in favor or against either party by reason of the authorship of any provisions hereof. The existence or absence of any term or condition of this AGREEMENT shall not be used in the
construction or interpretation of any other agreement between the parties. 



	11.3
	MARKINGS:
To the extent practicable and consistent with LICENSEE's customary practices, LICENSEE shall use markings as GTG may reasonably request from time to time, including, but
not limited to, marking the LICENSED SERVICES and/or documentation related thereto with patent number(s) as determined in LICENSEE's sole discretion.



	11.4
	MODIFICATION:
This AGREEMENT sets forth the entire agreement and understanding between the parties as to the subject matter of this AGREEMENT and merges all prior discussions between
the parties, and no one of the parties shall be bound by any modification of this AGREEMENT, or by any conditions, definitions, warranties, or representations with respect to the subject matter of
this AGREEMENT, other than as expressly provided for herein, or as duly set forth on or subsequent to the EFFECTIVE DATE in writing and signed by duly authorized representatives of the party to be
bound thereby.



	11.5
	CHOICE
OF LAW: This AGREEMENT and matters connected with the performance thereof shall be construed, interpreted, applied and governed in all respects in accordance with the laws of
the State of Delaware (excluding conflicts of laws).



	11.6
	ASSIGNMENT.
Neither party may assign this AGREEMENT without the prior written consent of the other party except in the event of the sale of all or substantially all of a party's
capital stock, business or assets whether by merger or otherwise pertaining to the subject matter of this AGREEMENT, such party may assign this AGREEMENT to its successor and shall provide notice of
such assignment to the other party; provided however, that prior to any assignment permitted herein by LICENSEE, LICENSEE's successor must expressly assume in writing LICENSEE's obligations under this
AGREEMENT and expressly acknowledge in writing that products and services of such successor existing prior to such assignment shall not be LICENSED SERVICES.



	11.7
	ATTORNEYS'
FEES: Upon resolution of any claim or controversy arising under this AGREEMENT, the prevailing party shall be awarded its reasonable attorneys' fees and costs in addition
to any other amount awarded.



	11.8
	EQUITABLE
REMEDIES: Each party acknowledges that its breach of any of its obligations set forth in Article VIII could result in immediate and irreparable damage to the other
party and that no adequate remedy may exist at law. Each party acknowledges and agrees that the other party may seek any available remedy, whether in law or equity, upon the other party's breach of
any of its obligations set forth in Article VIII.



	11.9
	INDEPENDENT
BUSINESS: The parties acknowledge that their business operations are completely independent and nether party shall at any time hold itself out as an agent or
representative of the other party. No partnership, joint venture, or other relationship shall be deemed to exist by virtue of this AGREEMENT.



	11.10
	INDEPENDENT
TERMS: All the terms of this AGREEMENT shall be independent and unconditional so that the performance of any one term shall not be subject to any set off or
counterclaim.



	11.11
	SEVERABILITY:
In the event any clause or term of this AGREEMENT is determined to be void, invalid, or unenforceable, the clause shall be reformed to the extent necessary in order to
overcome the limitation and give effect to the original intent of the parties and economic effect of the original provision and, as revised this AGREEMENT shall remain in full force and effect. 


9







 
	11.12
	HEADINGS:
The headings contained within this AGREEMENT are for convenience and reference purposes only. They do not form a part hereof and shall not affect the meaning or
interpretation of this AGREEMENT.



	11.13
	FURTHER
ASSURANCES: The parties hereto shall execute such further documents and perform such further acts as may be necessary to comply with the terms of this AGREEMENT and
consummate the transactions herein provided.



	11.14
	FORCE
MAJEURE: Neither party shall be held responsible if the fulfillment of any terms or provisions of this AGREEMENT are delayed or prevented by wars, revolutions, fires, floods,
acts of God, acts of terrorism whether actual or threatened, or other causes similar to those enumerated and not within the control of the party whose performance is interfered with, and which by the
exercise of reasonable diligence, the party is unable to prevent.



	11.15
	COUNTERPARTS:
This AGREEMENT may be executed in counterparts (and evidenced by facsimile signatures), each of which will be deemed an original and all of which together constitute
one instrument. 


[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK] 


10







 

        IN
WITNESS WHEREOF, the parties hereto have caused their authorized representatives to execute this AGREEMENT. 



	

GTG:	
 	

LICENSEE:
	 	 	 	 	 	 	 
	GENETIC TECHNOLOGIES LIMITED	 	LABORATORY CORPORATION OF AMERICA HOLDINGS
	 	 	 	 	 	 	 
	By:	 	 	 	By:	 	 
	 	 	
	 	 	 	

	 	 	 	 	 	 	 
	
 Printed Name/Date	 	
 Printed Name/Date
	 	 	 	 	 	 	 
	
 Title	 	 	 	 
	 	 	 	 	
 Title




11







 
Exhibit A

Licensed Patents  


        United States Patent No. 5,192,659 


        United
States Patent No. 5,612,179 


        United
States Patent No. 5,789,568 


        United
States Patent No. 5,851,762 


        United
States Patent No. 5,096,557 


[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK] 


12











QuickLinks



Exhibit 4.11


LICENSE AGREEMENT